Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Drug resistance in Mycobacterium tuberculosis and targeting the l,d-transpeptidase enzyme.

Gokulan K, Varughese KI.

Drug Dev Res. 2019 Feb;80(1):11-18. doi: 10.1002/ddr.21455. Epub 2018 Oct 12. Review.

PMID:
30312987
2.

ALS-causing mutations in profilin-1 alter its conformational dynamics: A computational approach to explain propensity for aggregation.

Kiaei M, Balasubramaniam M, Govind Kumar V, Shmookler Reis RJ, Moradi M, Varughese KI.

Sci Rep. 2018 Aug 30;8(1):13102. doi: 10.1038/s41598-018-31199-7.

3.

Structural origins of hemostasis and adaptive immunity.

Ware J, Varughese KI.

Res Pract Thromb Haemost. 2017 Sep 26;1(2):286-290. doi: 10.1002/rth2.12045. eCollection 2017 Oct.

4.

Structure and Inhibitor Specificity of L,D-Transpeptidase (LdtMt2) from Mycobacterium tuberculosis and Antibiotic Resistance: Calcium Binding Promotes Dimer Formation.

Gokulan K, Khare S, Cerniglia CE, Foley SL, Varughese KI.

AAPS J. 2018 Mar 9;20(2):44. doi: 10.1208/s12248-018-0193-x.

PMID:
29524047
5.

LOX-1 in Atherosclerosis and Myocardial Ischemia: Biology, Genetics, and Modulation.

Pothineni NVK, Karathanasis SK, Ding Z, Arulandu A, Varughese KI, Mehta JL.

J Am Coll Cardiol. 2017 Jun 6;69(22):2759-2768. doi: 10.1016/j.jacc.2017.04.010. Review.

6.

LIS1 Regulates Osteoclastogenesis through Modulation of M-SCF and RANKL Signaling Pathways and CDC42.

Ye S, Fujiwara T, Zhou J, Varughese KI, Zhao H.

Int J Biol Sci. 2016 Nov 25;12(12):1488-1499. eCollection 2016.

7.

PLEKHM1/DEF8/RAB7 complex regulates lysosome positioning and bone homeostasis.

Fujiwara T, Ye S, Castro-Gomes T, Winchell CG, Andrews NW, Voth DE, Varughese KI, Mackintosh SG, Feng Y, Pavlos N, Nakamura T, Manolagas SC, Zhao H.

JCI Insight. 2016 Oct 20;1(17):e86330. doi: 10.1172/jci.insight.86330.

8.

Corrigendum to "Sesquiterpene lactones from Gynoxys verrucosa and their anti-MRSA activity" [J. Ethnopharmacol. 137 (2011) 1055-1059].

Ordóñez PE, Quave CL, Reynolds WF, Varughese KI, Berry B, Breen PJ, Malagón O, Vidari G, Smeltzer MS, Compadre CM.

J Ethnopharmacol. 2016 Jun 20;186:392. doi: 10.1016/j.jep.2016.04.022. Epub 2016 May 8. No abstract available.

PMID:
27165010
9.

Analysis of Protein-protein Interaction Interface between Yeast Mitochondrial Proteins Rim1 and Pif1 Using Chemical Cross-linking Mass Spectrometry.

Zybailov B, Gokulan K, Wiese J, Ramanagoudr-Bhojappa R, Byrd AK, Glazko G, Jaiswal M, Mackintosh S, Varughese KI, Raney KD.

J Proteomics Bioinform. 2015 Nov;8(11):243-252. Epub 2015 Nov 19.

10.

Structure-based Design Targeted at LOX-1, a Receptor for Oxidized Low-Density Lipoprotein.

Thakkar S, Wang X, Khaidakov M, Dai Y, Gokulan K, Mehta JL, Varughese KI.

Sci Rep. 2015 Nov 18;5:16740. doi: 10.1038/srep16740.

11.

Cross-talk between LOX-1 and PCSK9 in vascular tissues.

Ding Z, Liu S, Wang X, Deng X, Fan Y, Shahanawaz J, Shmookler Reis RJ, Varughese KI, Sawamura T, Mehta JL.

Cardiovasc Res. 2015 Sep 1;107(4):556-67. doi: 10.1093/cvr/cvv178. Epub 2015 Jun 19.

PMID:
26092101
12.

Molecular dynamics guided design of tocoflexol: a new radioprotectant tocotrienol with enhanced bioavailability.

Compadre CM, Singh A, Thakkar S, Zheng G, Breen PJ, Ghosh S, Kiaei M, Boerma M, Varughese KI, Hauer-Jensen M.

Drug Dev Res. 2014 Feb;75(1):10-22. doi: 10.1002/ddr.21162. Epub 2013 Dec 26.

13.

(E)-13-(4-Amino-phen-yl)parthenolide.

Penthala NR, Janganati V, Parkin S, Varughese KI, Crooks PA.

Acta Crystallogr Sect E Struct Rep Online. 2013 Oct 26;69(Pt 11):o1709-10. doi: 10.1107/S1600536813028730. eCollection 2013 Oct 26.

14.

Affinity improvement of a therapeutic antibody to methamphetamine and amphetamine through structure-based antibody engineering.

Thakkar S, Nanaware-Kharade N, Celikel R, Peterson EC, Varughese KI.

Sci Rep. 2014 Jan 14;4:3673. doi: 10.1038/srep03673.

15.

Structural characterization of a therapeutic anti-methamphetamine antibody fragment: oligomerization and binding of active metabolites.

Peterson EC, Celikel R, Gokulan K, Varughese KI.

PLoS One. 2013 Dec 5;8(12):e82690. doi: 10.1371/journal.pone.0082690. eCollection 2013.

16.

ATP forms a stable complex with the essential histidine kinase WalK (YycG) domain.

Celikel R, Veldore VH, Mathews I, Devine KM, Varughese KI.

Acta Crystallogr D Biol Crystallogr. 2012 Jul;68(Pt 7):839-45. doi: 10.1107/S090744491201373X. Epub 2012 Jun 15.

17.

Sesquiterpene lactones from Gynoxys verrucosa and their anti-MRSA activity.

Ordóñez PE, Quave CL, Reynolds WF, Varughese KI, Berry B, Breen PJ, Malagón O, Vidari G, Smeltzer MS, Compadre CM.

J Ethnopharmacol. 2011 Sep 2;137(2):1055-9. doi: 10.1016/j.jep.2011.07.012. Epub 2011 Jul 12. Erratum in: J Ethnopharmacol. 2016 Jun 20;186:392. Vidari G [added].

18.

Binding of alpha-thrombin to surface-anchored platelet glycoprotein Ib(alpha) sulfotyrosines through a two-site mechanism involving exosite I.

Zarpellon A, Celikel R, Roberts JR, McClintock RA, Mendolicchio GL, Moore KL, Jing H, Varughese KI, Ruggeri ZM.

Proc Natl Acad Sci U S A. 2011 May 24;108(21):8628-33. doi: 10.1073/pnas.1017042108. Epub 2011 May 9.

19.
20.

Crystal structure of the transcriptional repressor PagR of Bacillus anthracis.

Zhao H, Volkov A, Veldore VH, Hoch JA, Varughese KI.

Microbiology. 2010 Feb;156(Pt 2):385-91. doi: 10.1099/mic.0.033548-0. Epub 2009 Nov 19.

21.

Crystal structures of a therapeutic single chain antibody in complex with two drugs of abuse-Methamphetamine and 3,4-methylenedioxymethamphetamine.

Celikel R, Peterson EC, Owens SM, Varughese KI.

Protein Sci. 2009 Nov;18(11):2336-45. doi: 10.1002/pro.244.

22.

In vivo relevance for platelet glycoprotein Ibalpha residue Tyr276 in thrombus formation.

Guerrero JA, Shafirstein G, Russell S, Varughese KI, Kanaji T, Liu J, Gartner TK, Bäumler W, Jarvis GE, Ware J.

J Thromb Haemost. 2008 Apr;6(4):684-91. doi: 10.1111/j.1538-7836.2008.02916.x.

23.

Platelet dysfunction and a high bone mass phenotype in a murine model of platelet-type von Willebrand disease.

Suva LJ, Hartman E, Dilley JD, Russell S, Akel NS, Skinner RA, Hogue WR, Budde U, Varughese KI, Kanaji T, Ware J.

Am J Pathol. 2008 Feb;172(2):430-9. doi: 10.2353/ajpath.2008.070417. Epub 2008 Jan 10.

24.

Sporulation phosphorelay proteins and their complexes: crystallographic characterization.

Varughese KI, Zhao H, Veldore VH, Zapf J.

Methods Enzymol. 2007;422:102-22.

PMID:
17628136
25.

The crystal structure of beryllofluoride Spo0F in complex with the phosphotransferase Spo0B represents a phosphotransfer pretransition state.

Varughese KI, Tsigelny I, Zhao H.

J Bacteriol. 2006 Jul;188(13):4970-7. Erratum in: J Bacteriol. 2007 Apr;189(8):3328.

26.
27.

Interactions between the YycFG and PhoPR two-component systems in Bacillus subtilis: the PhoR kinase phosphorylates the non-cognate YycF response regulator upon phosphate limitation.

Howell A, Dubrac S, Noone D, Varughese KI, Devine K.

Mol Microbiol. 2006 Feb;59(4):1199-215. Erratum in: Mol Microbiol. 2006 Apr;60(2):535.

28.

Rebuttal: beryllofluoride binding mimics phosphorylation of aspartate in response regulators.

Varughese KI.

J Bacteriol. 2005 Dec;187(24):8231. No abstract available.

29.

Conformational changes of Spo0F along the phosphotransfer pathway.

Varughese KI.

J Bacteriol. 2005 Dec;187(24):8221-7.

30.

A computational analysis on the specificity of interactions between histidine kinases and response regulators.

Mukhopadhyay D, Varughese KI.

J Biomol Struct Dyn. 2005 Apr;22(5):555-62.

PMID:
15702927
31.

Metals in the sporulation phosphorelay: manganese binding by the response regulator Spo0F.

Mukhopadhyay D, Sen U, Zapf J, Varughese KI.

Acta Crystallogr D Biol Crystallogr. 2004 Apr;60(Pt 4):638-45. Epub 2004 Mar 23.

PMID:
15039551
32.

Platinum-induced space-group transformation in crystals of the platelet glycoprotein Ib alpha N-terminal domain.

Varughese KI, Ruggeri ZM, Celikel R.

Acta Crystallogr D Biol Crystallogr. 2004 Mar;60(Pt 3):405-11. Epub 2004 Feb 25.

PMID:
14993663
33.

A single amino acid change in the binding pocket alters specificity of an anti-integrin antibody AP7.4 as revealed by its crystal structure.

Vasudevan S, Celikel R, Ruggeri ZM, Varughese KI, Kunicki TJ.

Blood Cells Mol Dis. 2004 Jan-Feb;32(1):176-81.

PMID:
14757433
34.

Structure of pteridine reductase (PTR1) from Leishmania tarentolae.

Zhao H, Bray T, Ouellette M, Zhao M, Ferre RA, Matthews D, Whiteley JM, Varughese KI.

Acta Crystallogr D Biol Crystallogr. 2003 Sep;59(Pt 9):1539-44. Epub 2003 Aug 19.

PMID:
12925782
35.

Modulation of alpha-thrombin function by distinct interactions with platelet glycoprotein Ibalpha.

Celikel R, McClintock RA, Roberts JR, Mendolicchio GL, Ware J, Varughese KI, Ruggeri ZM.

Science. 2003 Jul 11;301(5630):218-21.

36.

Red cell adenylate kinase deficiency: molecular study of 3 new mutations (118G>A, 190G>A, and GAC deletion) associated with hereditary nonspherocytic hemolytic anemia.

Corrons JL, Garcia E, Tusell JJ, Varughese KI, West C, Beutler E.

Blood. 2003 Jul 1;102(1):353-6. Epub 2003 Mar 20.

PMID:
12649162
37.

Structure and function of the von Willebrand factor A1 domain.

Varughese KI, Celikel R, Ruggeri ZM.

Curr Protein Pept Sci. 2002 Jun;3(3):301-12. Review.

PMID:
12188898
38.

DNA complexed structure of the key transcription factor initiating development in sporulating bacteria.

Zhao H, Msadek T, Zapf J, Madhusudan, Hoch JA, Varughese KI.

Structure. 2002 Aug;10(8):1041-50.

39.

Molecular recognition of bacterial phosphorelay proteins.

Varughese KI.

Curr Opin Microbiol. 2002 Apr;5(2):142-8. Review.

PMID:
11934609
40.

Keeping signals straight in phosphorelay signal transduction.

Hoch JA, Varughese KI.

J Bacteriol. 2001 Sep;183(17):4941-9. Review. No abstract available.

41.

Crystal structure of the von Willebrand factor modulator botrocetin.

Sen U, Vasudevan S, Subbarao G, McClintock RA, Celikel R, Ruggeri ZM, Varughese KI.

Biochemistry. 2001 Jan 16;40(2):345-52.

PMID:
11148028
42.

von Willebrand factor conformation and adhesive function is modulated by an internalized water molecule.

Celikel R, Ruggeri ZM, Varughese KI.

Nat Struct Biol. 2000 Oct;7(10):881-4.

PMID:
11017197
44.

Modeling and functional analysis of the interaction between von Willebrand factor A1 domain and glycoprotein Ibalpha.

Vasudevan S, Roberts JR, McClintock RA, Dent JA, Celikel R, Ware J, Varughese KI, Ruggeri ZM.

J Biol Chem. 2000 Apr 28;275(17):12763-8.

45.

Comparative properties of three pteridine reductases.

Chang CF, Bray T, Varughese KI, Whiteley JM.

Adv Exp Med Biol. 1999;463:403-10. Review. No abstract available.

PMID:
10352712
46.
47.

Six previously undescribed pyruvate kinase mutations causing enzyme deficiency.

Demina A, Varughese KI, Barbot J, Forman L, Beutler E.

Blood. 1998 Jul 15;92(2):647-52.

PMID:
9657767
48.

A source of response regulator autophosphatase activity: the critical role of a residue adjacent to the Spo0F autophosphorylation active site.

Zapf J, Madhusudan M, Grimshaw CE, Hoch JA, Varughese KI, Whiteley JM.

Biochemistry. 1998 May 26;37(21):7725-32.

PMID:
9601032
49.

Crystal structure of the von Willebrand factor A1 domain in complex with the function blocking NMC-4 Fab.

Celikel R, Varughese KI, Madhusudan, Yoshioka A, Ware J, Ruggeri ZM.

Nat Struct Biol. 1998 Mar;5(3):189-94.

PMID:
9501911
50.

A response regulatory protein with the site of phosphorylation blocked by an arginine interaction: crystal structure of Spo0F from Bacillus subtilis.

Madhusudan M, Zapf J, Hoch JA, Whiteley JM, Xuong NH, Varughese KI.

Biochemistry. 1997 Oct 21;36(42):12739-45.

PMID:
9335530

Supplemental Content

Loading ...
Support Center